Pausing Medicaid eligibility determinations during COVID-19 pandemic linked to increased risk for having no prescriptions and cash-pay prescriptions
However, increased risk of self-harm is seen before initiation of treatment, during initial phase of treatment, and after discontinuation
Role of psychotherapy increasing in mental health care, while use of psychotropic meds without psychotherapy decreasing
Increases in hemodynamic signs seen with amphetamines, atomoxetine, lisdexamfetamine, methylphenidate, and viloxazine
Higher prevalence ratios for misuse, prescription stimulant use disorder seen for those using amphetamines versus methylphenidate
Higher lithium serum levels linked to elevated rates of hypothyroidism, hyperthyroidism, and CKD3+
Two systematic reviews revealed very low-certainty evidence on outcomes for people with gender dysphoria
Findings seen among adolescent and young adult Medicaid enrollees
Drug is the first and only approved monotherapy for refractory major depressive disorder
Antimicrobials, vaccines, anti-inflammatories linked to reduced risk for Alzheimer disease and dementia; antipsychotics and diabetes drugs tied to higher risk